Cynthia Lynn Bristow

US Patent:

7833735, Nov 16, 2010

Filed:

Jun 13, 2006

Appl. No.:

11/452028

Inventors:

Cynthia L. Bristow - New York NY, US

International Classification:

G01N 33/573
G01N 33/574

US Classification:

435 723, 435 724, 435 74, 435962

Abstract:

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also “binding sites”) on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by anyone of a number of standard techniques, (e. g. , confocal laser scanning microscopy and flow cytometry).

US Patent:

20020004212, Jan 10, 2002

Filed:

Jul 5, 2001

Appl. No.:

09/899498

Inventors:

Cynthia Bristow - New York NY, US

International Classification:

G01N033/567
C12Q001/70

US Classification:

435/007210, 435/005000

Abstract:

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also “binding sites”) on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by any one of a number of standard techniques, (e.g., confocal laser scanning microscopy and flow cytometry).

US Patent:

20020004477, Jan 10, 2002

Filed:

Jul 5, 2001

Appl. No.:

09/899500

Inventors:

Cynthia Bristow - New York NY, US

International Classification:

A61K031/00

US Classification:

514/001000

Abstract:

A method for the treatment of asymtomatic HIV seropositive individuals to inhibit onset of an AIDS infection and, for suppression of propagation of HIV infections in individuals with a fully developed AIDS infection. The method consists of administering a therapeutic effective amount of a modified {acute over ()}Proteinase Inhibitor (m{acute over ()}PI) to an individual within the effected population so as to inhibit and/or prevent {acute over ()} PI facilitated HIV entry into healthy/uninfected cells.

US Patent:

20020009788, Jan 24, 2002

Filed:

Jun 29, 2001

Appl. No.:

09/896743

Inventors:

Cynthia Bristow - New York NY, US

International Classification:

A61K038/43
C12N009/99

US Classification:

435/184000, 424/094100

Abstract:

A method for modulation of plasma membrane associated Human Leukocyte Elastase (HLE) to inflammatory states by interaction of HLE with an antagonist to inhibit HLE and thereby interruption in plasma associated events (e.g. HIV disease progression, bacterial infections and autoimmune diseases), which are responsive/sensitive to such inflammation. The antagonist suitable for use in this invention is designed to interact with each of the catalytic triad of the HLE plasma membranes protein and the lipid interactive amino acids of the HLE plasma membrane protein.

US Patent:

20030138427, Jul 24, 2003

Filed:

Jan 28, 2003

Appl. No.:

10/353243

Inventors:

Cynthia Bristow - New York NY, US

International Classification:

A61K039/395
A61K038/17
C12N009/99

US Classification:

424/146100, 514/012000, 435/184000

Abstract:

A method for modulation of plasma membrane associated Human Leukocyte Elastase (HLE) to inflammatory states by interaction of HLE with an antagonist to inhibit HLE and thereby interruption in plasma associated events (e.g. HIV disease progression, bacterial infections and autoimmune diseases), which are responsive/sensitive to such inflammation. The antagonist suitable for use in this invention is designed to interact with each of the catalytic triad of the HLE plasma membranes protein and the lipid interactive amino acids of the HLE plasma membrane protein.

US Patent:

20050164315, Jul 28, 2005

Filed:

Feb 22, 2005

Appl. No.:

11/062982

Inventors:

Cynthia Bristow - New York NY, US

International Classification:

G01N033/574

US Classification:

435007230

Abstract:

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also “binding sites”) on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by any one of a number of standard techniques, (e.g., confocal laser scanning microscopy and flow cytometry).

US Patent:

20060183214, Aug 17, 2006

Filed:

Jan 18, 2006

Appl. No.:

11/334697

Inventors:

Cynthia Bristow - New York NY, US

International Classification:

C12N 9/66

US Classification:

435218000, 435183000, 435195000, 435007100

Abstract:

A method for modulation of plasma membrane associated Human Leukocyte Elastase (HLE) to inflammatory states by interaction of HLE with an antagonist to inhibit HLE and thereby interruption in plasma associated events (e.g. HIV disease progression, bacterial infections and autoimmune diseases), which are responsive/sensitive to such inflammation. The antagonist suitable for use in this invention is designed to interact with each of the catalytic triad of the HLE plasma membranes protein and the lipid interactive amino acids of the HLE plasma membrane protein.

US Patent:

20080009442, Jan 10, 2008

Filed:

Dec 5, 2006

Appl. No.:

11/566903

Inventors:

Cynthia Bristow - New York NY, US

Assignee:

Institute for Human Genetics and Biochemistry - New York NY

International Classification:

A61K 38/17
A61P 31/04
A61P 31/18
A61P 35/00
A61P 35/02
A61P 37/00
A61P 9/10
C07K 14/435
C12Q 1/37

US Classification:

514012000, 435023000, 530350000

Abstract:

A previously unrecognized fundamental property of αPI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified αPI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HIV-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of αPI with its receptors, HLEand LRP, influences the level of cells of different lineages. Genetic and proteolytic modification of αPI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.